Novavax Overview

  • Year Founded
  • 1987

Year Founded

  • Status
  • Public

  • Employees
  • 1,274

Employees

  • Stock Symbol
  • NVAX

Stock Symbol

  • Investments
  • 3

  • Share Price
  • $3.98
  • (As of Wednesday Closing)

Novavax General Information

Description

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. Novavax develops product candidates geared toward all age demographics of the general population.

Contact Information

Website
www.novavax.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 21 Firstfield Road
  • Gaithersburg, MD 20878
  • United States
+1 (240) 000-0000

Novavax Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novavax Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.98 $4.13 $3.53 - $11.36 $473M 119M 7.59M -$6.22

Novavax Financials Summary

In Thousands,
USD
TTM 30-Sep-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 423,579 41,377 9,307,338 7,235,150
Revenue 973,730 1,981,872 1,146,290 475,598
EBITDA (498,286) (604,713) (1,680,748) (398,229)
Net Income (548,922) (657,939) (1,743,751) (418,259)
Total Assets 1,657,157 2,258,679 2,576,753 1,582,479
Total Debt 222,111 549,781 453,991 467,980
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Novavax Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novavax‘s full profile, request access.

Request a free trial

Novavax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development wi
Biotechnology
Gaithersburg, MD
1,274 As of 2023
00000
0.000 0000-00-00
000000000 00000

000000

iat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culp
0000000000000
Emeryville, CA
000 As of 0000
00000
000000000 00000

000000

m veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commod
0000 000000000
Cambridge, MA
0000 As of 0000
00.00
00000000000 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Novavax Competitors (46)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Dynavax Technologies Formerly VC-backed Emeryville, CA 000 00000 000000000 00000
Moderna Formerly VC-backed Cambridge, MA 0000 00.00 00000000000 00.00
CureVac Formerly VC-backed Tubingen, Germany 0000 00.000 00000000 00.000
Valneva Formerly VC-backed Saint-Herblain, France 000 00000 00000000 00000
Cytodyn Formerly Angel backed Vancouver, WA 00 00000 000000000 00000
You’re viewing 5 of 46 competitors. Get the full list »

Novavax Patents

Novavax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220354944-A1 Coronavirus and influenza compositions and methods for using them Pending 05-May-2021 000000000
AU-2022270082-A1 Coronavirus and influenza compositions and methods for using them Pending 05-May-2021 000000000
CA-3217591-A1 Coronavirus and influenza compositions and methods for using them Pending 05-May-2021 000000000
US-20220332765-A1 Coronavirus vaccine formulations Pending 22-Mar-2021 0000000000
AU-2022245141-A1 Coronavirus vaccine formulations Pending 22-Mar-2021 A61P31/14
To view Novavax’s complete patent history, request access »

Novavax Executive Team (31)

Name Title Board Seat Contact Info
John Jacobs Chief Executive Officer & Board Member
John Trizzino Executive Vice President, Chief Commercial Officer & Chief Business Officer
Filip Dubovsky MD President
James Kelly Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Gregory Covino Executive Advisor
You’re viewing 5 of 31 executive team members. Get the full list »

Novavax Board Members (12)

Name Representing Role Since
00000 0000 Self Director 000 0000
00000 00000 00 Self Director and Member of Audit Committee 000 0000
00000 00000 00.0 Self Chairman & Board Member 000 0000
0000 000000 Novavax Chief Executive Officer & Board Member 000 0000
00000000 0000000 Novavax Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Novavax Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novavax Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Novavax‘s full profile, request access.

Request a free trial

Novavax Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Novavax CZ 27-May-2020 0000000000 00000 Pharmaceuticals 0000000 0
Novavax (Maryland) 22-Aug-2013 0000000000 0000 Drug Discovery 0000 0000
CPL Biologicals 01-Jan-2009 Joint Venture Biotechnology
To view Novavax’s complete investments and acquisitions history, request access »

Novavax Subsidiaries (1)

Company Name Industry Location Founded
Novavax CZ Pharmaceuticals Jevany, Czech Republic
To view Novavax’s complete subsidiaries history, request access »

Novavax ESG

Risk Overview

Risk Rating

Updated January, 28, 2023

32.76 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,605

Rank

00.0

Percentile

Pharmaceuticals

Industry

00 of 870

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 386

Rank

00.00

Percentile

To view Novavax’s complete esg history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »